Why the study?
Does postoperative adjuvant chemotherapy or radiation therapy improve survival or local recurrence-free survival in adults with small soft-tissue sarcoma of the extremity?
Does postoperative adjuvant chemotherapy or radiation therapy improve survival or local recurrence-free survival in adults with small soft-tissue sarcoma of the extremity?
Small soft-tissue sarcomas of the extremity have a favorable prognosis with a 94% 5-year survival rate, and adjuvant therapy does not appear to improve survival or recurrence-free survival.
Answers are grounded in this paper and cite their sources.
Supports observation alone for small extremity soft-tissue sarcomas; hypothesis-generating and requires randomized confirmation.
To determine the significance of small (< or = 5 cm in diameter) soft-tissue sarcoma of the extremity, 174 adult patients were identified from information that had been entered prospectively into a database of 1742 patients between July 1982 and December 1990. Median follow-up was 48 months. The majority of tumors were high grade (n = 114; 66%). Local recurrence (n = 17) was seen in patients with both high-grade (11%) and low-grade tumors (7%). Distant metastases were seen in 7% of high-grade tumors and in no low-grade tumors. The overall 5-year survival rate was 94% for all patients. Grade, depth, location, type of operation, and sex did not affect 5-year survival or local recurrence-free survival. Neither postoperative adjuvant chemotherapy nor radiation therapy resulted in superior 5-year survival or local recurrence-free survival when compared with no postoperative treatment. The prognosis of these lesions is favorable, and no additional prognostic factors were identified. Inclusion of these patients into adjuvant therapy trials examining survival is inappropriate.
No takes yet. Share an insight, caveat, or question.
R. Geer (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: